Dixin (Dixin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHydroxymethylquinoxaline dioxideHydroxymethylquinoxaline dioxide
Similar drugsTo uncover
  • Viuxidin®
    concentrate d / infusion 
    TRIVIUM-XXI, LLC     Russia
  • Dixin
    solution c / cavity externally 
    ATOLL, LLC     Russia
  • Dioxydin®
    solution d / infusion externally 
    VALENTA PHARM, PAO     Russia
  • Dioxydin
    solution c / cavity externally 
    BIOSINTEZ, PAO     Russia
  • Dioxydin
    ointment externally 
    BIOSINTEZ, PAO     Russia
  • Dioxydin®
    ointment cutaneous externally 
    NIZHFARM, JSC     Russia
  • Dioxydin
    solution in / in 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Imibact®
    solution c / cavity externally 
    SYNTHESIS, OJSC     Russia
  • Imibact®
    solution locally in / in externally 
    SYNTHESIS, OJSC     Russia
  • Imibact®
    ointment locally externally 
    SYNTHESIS, OJSC     Russia
  • Urotravenol
    solution v / vesular 
    MTS MEDICINE, LLC     Russia
    • Dosage form: & nbspSolution for intracavitary and external use.
    Composition:
    Per 1 ml:
    Active substance: hydroxymethylquinoxaline dioxide 10.0 mg.
    Excipient: water for injection - up to 1.0 ml.
    Description:Transparent greenish-yellow liquid.
    Note. In the course of storage, the precipitation of crystals of hydroxymethylquinoxaline dioxide in ampoules with a solution is allowed. In the case of the precipitation of crystals of hydroxymethylquinoxaline dioxide in ampoules with a solution, they are dissolved by heating the ampoules with the solution in a boiling water bath with shaking until the crystals are completely dissolved(clear solution). If the crystals do not fall again upon cooling to 36-38 ° C, the preparation is usable.
    Pharmacotherapeutic group:antimicrobial agent - quinoxaline
    ATX: & nbsp

    J.01.X.X   Other antibacterial drugs

    Pharmacodynamics:
    Antibacterial preparation of a broad spectrum of action from the group of quinoxaline derivatives. It is active against Proteus vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli. Shigella dyscntcriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Salmonella spp., Staphylococcus spp., Streptococcus spp., Pathogenic anaerobes (Clostridium pcrlringcns). It acts on strains of bacteria resistant to other antimicrobial medicines, including antibiotics.
    Possible development of drug resistance of bacteria. Treatment of burns and purulent-necrotic wounds, promotes faster cleaning of the wound surface, stimulates reparative regeneration and marginal enanthelization and favorably influences the course of the wound process.
    The mechanism of bactericidal action of hydroxymethylquinoxaline dioxide is the damage to the biosynthesis of the DNA of a microbial cell.
    Pharmacokinetics:When topical application is partially absorbed from the wound or burn surface, it is excreted by the kidneys.
    Indications:
    Purulent bacterial infections caused by sensitive microflora when other chemotherapeutic agents are ineffective or poorly tolerated.
    Intracisal administration - Purulent processes in the thoracic and abdominal cavity: purulent pleurisy, empyema of the pleura, peritonitis; cystitis, prevention of infectious complications after catheterization of the bladder; wounds with the presence of deep purulent cavities (abscess of soft tissues, phlegmon of the pelvic fat, postoperative wounds of the urinary and bile ducts, purulent mastitis).
    External application - wound and burn infection (superficial and deep wounds of various locations, phlegmon soft tissue, purulent wounds in osteomyelitis).
    Contraindications:
    Hypersensitivity to hydroxymethylquinoxaline dioxide, other drugs of the quinoxaline group, adrenal insufficiency (including in the anamnesis), pregnancy, lactation period, children's age (under 18 years).
    Carefully:
    Renal failure.
    Pregnancy and lactation:During pregnancy and during breastfeeding, the use of the drug is contraindicated.
    In preclinical studies it was shown that hydroxymethylstyrene and oxalindioxide has a teratogenic and embryotoxic effect, has mutagenic properties. The use of the drug during lactation is possible only after the transfer of the child to artificial feeding.
    Dosing and Administration:
    Apply externally, intracavitary.
    Intracavernal administration.
    Depending on the size of the purulent cavity, 10 to 50 ml of a 1% solution of hydroxymethylquinoxaline dioxide are administered per day. A solution of hydroxymethylquinoxaline dioxide is injected into the cavity through a catheter, a drainage tube or a syringe.
    The maximum daily dose for administration in the cavity is 70 ml of a 1% solution.
    The drug is injected into the cavity usually once a day. According to the indications, it is possible to administer a daily dose in two divided doses. With good tolerability, the drug can be administered daily for 3 weeks or more. If necessary, repeat courses are conducted after 1-1.5 months.
    For patients with impaired renal function, the dose of the drug is reduced by a factor of 2. In elderly patients, a dose reduction may be required in case of renal dysfunction.
    External application.
    Apply 0.1-1% solutions of hydroxymethylquinoxaline dioxide. To obtain a solution of the desired concentration, the drug is diluted with a sterile 0.9% solution of sodium chloride or water for injection. To treat superficial purulent wounds on the wound surface, previously cleared of purulent necrotic masses, apply wipes moistened with 0.5-1% solution of hydroxymethylquinoxaline dioxide. Bandages are changed daily or every other day, depending on the condition of the wound or the course of the wound process. Deep wounds after treatment loosely swabbed with tampons moistened with a 1% solution of hydroxymethylquinoxaline dioxide. Dressings are done once a day.
    The maximum daily dose of hydroxymethylquinoxaline dioxide is 2.5 g (250 ml of 1% solution). Duration of treatment - up to 3 weeks. To treat deep purulent wounds in osteomyelitis (brushes of the hand, foot), apply 0,5-1% solution of the drug in the form of trays or special treatment of the wound with the drug for 15-20 minutes (insertion of the solution into the wound for the ego), followed by bandaging , moistened with a 1% solution. To prevent infections after surgery, 0.1-0.5% solution of the drug is used.According to the indications (patients with osteomyelitis) and with good tolerability treatment can be carried out daily for 1.5-2 months.
    Side effects:
    With intracavitary injection, headache, chills, hyperthermia, dyspeptic disorders, convulsive muscle contractions, allergic reactions, photosensitizing effect (the appearance of pigmented spots on the body when exposed to sunlight) are possible.
    With external application - okoloranevoy dermatitis, itching.
    Overdose:When an overdose of the drug may develop acute adrenal insufficiency, which requires the immediate withdrawal of the drug and appropriate replacement hormone therapy.
    Interaction:There is no information on the interaction of the drug with other drugs.
    Special instructions:
    The drug is used under strict medical supervision in a hospital. Hydroxymethylquinoxaline dioxide appoint only adults. Before the beginning of the course of treatment, a drug tolerance test is carried out, for which 10 ml of a 1% solution is injected into the cavity. If there are no side effects during 3-6 hours (dizziness, chills, fever), they begin course treatment.Otherwise, the drug is not prescribed.
    Hydroxymethylquinoxaline dioxide is administered only in severe forms
    infectious diseases or in the ineffectiveness of other antibacterial drugs, including cephalosporins of II-IV generations, fluoroquinolones, carbapenems. In chronic renal failure, the dose is reduced.
    When pigmented spots appear, the duration of dosing is increased to 1.5-2 hours, the dose is reduced, antihistamine drugs are prescribed, or hydroxy-methyl chinoxalide dioxide is abolished.
    To prevent adverse reactions, it is recommended to use in combination with antihistamines and calcium preparations.
    If adverse reactions occur, reduce the dose, prescribe antihistamine medications, and if necessary, cancel the drug.
    When used in elderly people, it is necessary to take into account the age-related decrease in the function of the nights, which may require a reduction in the dose of the drug.
    In case of precipitation of crystals during storage, they are dissolved by heating the ampoules in a boiling water bath with shaking until the crystals are completely dissolved (clear solution).If the crystals do not fall again upon cooling to 36-38 ° C, the preparation is usable.
    The drug can not be used for intravenous administration due to instability of the solution when stored at low temperatures.
    Effect on the ability to drive transp. cf. and fur:During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.
    Form release / dosage:
    Solution for intracavitary and topical administration 10 mg / ml.
    Packaging:By 5 or 10 ml into ampoules of colorless neutral glass type I according to ISO 9187 with a colored break ring or with a colored dot and a notch or without a kink ring, a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and alphanumeric coding can additionally be applied to the ampoules.
    5 ampoules per circuit cell packaging made of polyvinylchloride film and aluminum foil foil or polymer film or without foil and without film.Or 5 ampoules are placed in a prefabricated form (gray) made of cardboard with cells for packing ampoules.
    One or two contour squares or cardboard warming together with an instruction for use and a scarifier or knife with an ampoule or without a scarifier and a knife ampoule are placed in a cardboard package (bundle).
    Storage conditions:In a dark place at a temperature of 15 to 25 ° C Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-003345
    Date of registration:03.12.2015
    The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp28.12.2015
    Illustrated instructions
      Instructions
      Up